Scientists from the Garvan Institute of Medical Research have developed what could be the next big blockbuster treatment for inflammatory diseases such as rheumatoid arthritis and asthma. This discovery is being commercialised by G2 Therapies Ltd, a biotechnology company founded by Garvan, which today announced the signing of an AU$135 million research, development and licensing agreement with Danish healthcare company, Novo Nordisk. The terms of the agreement include an upfront payment and other success-based payments to a potential total of around US$100 million (A$135 million), plus royalties on commercialised therapeutics. The partnership will enable the new therapy to be taken through to human clinical trials.
